SCHEDULE 13G/A: RA Capital Boosts Dianthus Stake to 9.5%

RA Capital Management and its affiliates reported a 9.5% beneficial ownership stake in Dianthus Therapeutics, Inc., totaling 3,866,733 shares.

Summary

• RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. (collectively, the "Reporting Persons") beneficially own 3,866,733 shares of Dianthus Therapeutics, Inc. common stock.
• This ownership represents 9.5% of the company's outstanding common stock.
• The stake comprises 2,866,733 shares of common stock directly held by the Fund and pre-funded warrants exercisable for an additional 1,000,000 shares of common stock.
• The 9.5% ownership percentage is calculated based on a total of 40,816,224 shares, which includes 32,188,345 shares outstanding as of August 6, 2025, 7,627,879 shares from a public offering described in a September 2025 prospectus supplement, and the 1,000,000 shares issuable from the pre-funded warrants.
• RA Capital Management, L.P. acts as the investment adviser for RA Capital Healthcare Fund, L.P., holding sole voting and dispositive power over the securities in the Fund's portfolio.
• Peter Kolchinsky and Rajeev Shah are the controlling persons of RA Capital Management GP, LLC, the general partner of RA Capital Management, L.P.
• The Reporting Persons explicitly disclaim status as a "group" for the purposes of this Schedule 13G.

Sentiment

Score: 8

Explanation: The disclosure of a 9.5% beneficial ownership by RA Capital Management, a highly respected healthcare-focused investment firm, indicates strong institutional confidence in Dianthus Therapeutics. This level of investment often suggests a positive long-term view on the company's prospects, pipeline, or strategic direction.

Positives

• A significant institutional investment by RA Capital Management, a prominent healthcare-focused investment firm, signals strong confidence in Dianthus Therapeutics, Inc.'s potential.
• The 9.5% stake indicates a substantial long-term interest and commitment to the company's future prospects.

Risks

• The filing itself does not detail specific risks of Dianthus Therapeutics, Inc.; it solely reports beneficial ownership.

Future Outlook

NA

Industry Context

RA Capital Management is a well-known investment firm specializing in the life sciences and healthcare sectors. Their significant stake in Dianthus Therapeutics suggests a belief in the company's potential within the biotechnology or pharmaceutical industry, often indicating a positive view on its pipeline or strategic direction.

Comparison to Industry Standards

• A 9.5% stake by a specialized institutional investor like RA Capital Management is a substantial position, often seen as a strong vote of confidence in a small to mid-cap biotechnology company.
• Such an investment size is comparable to significant early-stage or growth-stage investments made by dedicated healthcare funds in promising biotech firms, indicating a belief in the company's long-term value proposition.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake by RA Capital Management could be viewed positively, potentially increasing investor confidence and attracting further investment.
• Company Management: A large institutional investor often brings increased scrutiny and potential strategic input, which can influence management decisions.

Key Dates

Recommendation

The disclosure of a 9.5% beneficial ownership by RA Capital Management, a highly respected and specialized healthcare investment firm, is a strong positive signal. Such a significant stake suggests deep due diligence and a conviction in Dianthus Therapeutics' long-term potential, pipeline, or strategic value. This institutional backing can enhance market credibility and attract further investor interest, making it a compelling "buy" signal for investors looking for companies with strong institutional support in the biotech sector.

Keywords

Dianthus Therapeutics, RA Capital Management, Peter Kolchinsky, Rajeev Shah, beneficial ownership, Schedule 13G, common stock, pre-funded warrants, institutional investment, biotechnology, healthcare